SquareMind, a Paris-based AI and robotics company, has raised $18 million — including previously undisclosed pre-Series A financing — to bring Swan, the world's first full-body dermoscopy robot, to clinics in the United States and Europe. The round was led by Sonder Capital, the venture fund co-founded by Intuitive Surgical pioneer Fred Moll.
What Swan does
Swan is the first robot to capture standardized, full-body dermoscopic skin imaging, acting as an augmented dermatoscope that views the entire skin surface at the level usually reserved for examining individual moles up close. Image acquisition is automated, contactless and completed in minutes, then paired with AI software that helps physicians track new or changing lesions over time while retaining full clinical judgment.
Why it matters
Skin screening is the highest-volume procedure in dermatology, and demand is outpacing capacity as populations age and waitlists stretch for months. Time pressure leaves little room for thorough documentation — a problem given that about 80% of melanomas are new lesions. SquareMind argues that consistent, automated imaging can reduce clinician cognitive load and support earlier detection.
Backers and what comes next
Alongside Sonder Capital, the round drew Bpifrance's Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures and Teampact Ventures. Swan is already FDA-listed and CE-marked, clearing the way for commercial use, and the capital will scale SquareMind's commercial, engineering and support teams ahead of a near-term launch. The deal extends a busy run of medical-robotics milestones, from Intuitive's da Vinci 5 updates and Medtronic's Hugo expansion to CMR Surgical's Versius Plus launch.
Reporting based on coverage from SquareMind, Business Wire and The Robot Report.